ArticleThe Lancet regional health. Southeast Asia2025

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.

Subhash Thuluva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.